{
    "root": "be0210a1-cda6-4f01-af18-5b022bbc68a5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "liothyronine sodium",
    "value": "20250312",
    "ingredients": [
        {
            "name": "LIOTHYRONINE SODIUM",
            "code": "GCA9VV7D2N"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN TYPE B BOVINE (160 BLOOM)",
            "code": "1T8387508X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        }
    ],
    "indications": "Liothyronine is an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism (1.1) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer (1.2) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy (1.3) Limitations of Use: Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. (1) Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. (1)",
    "contraindications": "Administer liothyronine sodium tablets orally once daily and individual dosage according to patient response and laboratory findings (2.1) See full prescribing information for recommended dosage for hypothyroidism (2.2) TSH suppression in well-differentiated thyroid cancer (2.3) and for thyroid suppression test (2.4) When switching a patient to liothyronine sodium tablets discontinue levothyroxine therapy and initiate liothyronine sodium tablets at a low dosage. Gradually increase the dose according to the patientâ€™s response (2.5) Adequacy of therapy determined with periodic monitoring of TSH and T3 levels as well as clinical status (2.6)",
    "warningsAndPrecautions": "Product:    50090-7518\n                  NDC:    50090-7518-0   100 TABLET in a BOTTLE\n                  NDC:    50090-7518-1   90 TABLET in a BOTTLE",
    "adverseReactions": "Liothyronine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.3)]."
}